

Lack of benefits of mammalian target of rapamycin ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24429>

See Article on Page 627. Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) generally carries a dismal prognosis, with fewer than 10% amenable to resection and a median survival of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of rapamycin ...

Cited by: 4

Author: Neil Mehta, John P. Roberts, Francis Y. Yao

Publish Year: 2016

Survival Benefit of Liver Transplantation for ...

<https://journals.lww.com/transplantjournal/...>

Introduction

Materials and Methods

Results

Discussion

The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and hepatocellular carcinoma (HCC).¹ For patients with early-stage HCC, there are 3 curative options—ablation, hepatic resection, and liver transplant (LT).²⁻⁴ Since the inception of model for end-stage liver disease (MELD)-based allocation in 2002, waitlisted patients with HCC within Milan criteria have been eligible for automatic MELD exception point...

[See more on journals.lww.com](#)

PEOPLE ALSO ASK

Which is the best liver transplant for HCC?



What is the survival benefit of Lt over ablation?



What is the trend in transplantation?



[Feedback](#)

Liver Transplantation for Hepatocellular Carcinoma: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736995>

Microsoft Bing

Trends of Rapamycin in Survival Benefits of Liver Transplantation for Hep

ALL IMAGES VIDEOS

43,200 Results Any time

Mammalian Target of Rapamycin Inhibitors Are Associated ...

<https://pubmed.ncbi.nlm.nih.gov/24843720>

Abstract: Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppression regimen with antineoplastic effect.

Cited by: 158 Author: Evangelos Cholongitis, Chrysantti Manti...

Publish Year: 2014

Lack of benefits of mammalian target of rapamycin ...

<https://aasidpubs.onlineibrary.wiley.com/doi/full/10.1002/lt.24429>

Mar 06, 2019 - See Article on Page 527. Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) generally carries a dismal prognosis, with lower than 10% amenable to resection and a median survival of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of rapamycin ...

Cited by: 4 Author: Neil Mehta, John P. Roberts, Francis Y. Yao

Publish Year: 2016


Survival Benefit of Liver Transplantation for ...

<https://journals.wm.com/transplantjournal/>

INTRODUCTION: The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and hepatocellular carcinoma (HCC). 1 For patients with early-stage HCC, there are 3 options: resection, ablation, transplantation, and liver

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

- 📊 Rare (Fewer than 200,000 cases per year in US)
- 💉 May be preventable by vaccine
- 🏥 Often requires lab test or imaging
- 🏥 Treatable by a medical professional

Chat with Bing


Chatting with a search engine is so cool, right?

Say something...

21-Jul-2021 06:23PM

5601 words • 16 matches • 14 sources

FAQ

 iThenticate®

64372_Auto_Edited.docx

Quotations Excluded
Bibliography Excluded

4%
(0/100)

Name of Journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 64372

Manuscript Type: MINIREVIEWS

Trends of Rapamycin in Survival Benefits of Liver Transplantation for Hepatocellular Carcinoma

Rapamycin in hepatocellular carcinoma after transplantation

Yang Zhao, Yu Liu, Lin Zhou, Guo-sheng Du, Qiang He

Match Overview

1

Internet 49 words
crawled on 30-Aug-2019
tessera.spandidos-publications.com

1%

2

Internet 20 words
crawled on 08-Jul-2019
www.mhacjournals.com

<1%

3

Crossref 19 words
Sam E. Gigg, Gino I. Sam, Paul J. Gow, Neville D. Yeoma
rs. "Systematic review with meta-analysis: simolimus- or ev

<1%

4

Crossref 19 words
Yu Sun, Shuai Zhao, Xiaoli Li, Liang Yan, Jingcheng Wan
g, Diain Wang, Hui Chen, Jihang Dai, Jun He "Local applic

<1%

5

Internet 18 words
crawled on 17-May-2020
insights.ovid.com

<1%

6

Crossref 17 words
Andreea Y. Choo, Daniel K. Choo, J. Joseph Kim, David B. ...
Weiner. "Chapter 6 DNA Vaccination in Immunotherapy of

<1%

7

Internet 17 words
www.ncbi.nlm.nih.gov

<1%

8

Internet 13 words
crawled on 18-Oct-2020

<1%

Page: 1 of 15

Text-Only Report

国内版

国际版

Trends of rapamycin in survival benefits of liver transplantation for



ALL

IMAGES

VIDEOS

12,800 Results

Any time ▾

[Lack of benefits of mammalian target of rapamycin ...](#)

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.24429>

Mar 08, 2016 · See Article on Page 627. Recurrent **hepatocellular carcinoma** (HCC) after **liver transplantation** (LT) generally carries a dismal prognosis, with fewer than 10% amenable to resection and a median **survival** of only a year from diagnosis. 1, 2 Despite adherence to the Milan criteria, 3 HCC still recurs in 10%-15% after LT. 1 It has been postulated that calcineurin inhibitors (CNIs) may amplify HCC recurrence risk. 4 Immunosuppression based on mammalian target of rapamycin ...

Cited by: 4

Author: Neil Mehta, John P. Roberts, Francis Y. Yao

Publish Year: 2016

[Survival Benefit of Liver Transplantation for ...](#)

<https://journals.lww.com/transplantjournal/...>

INTRODUCTION. The rising prevalence of hepatitis C virus (HCV) and nonalcoholic fatty liver disease has led to a marked increase in the incidence of cirrhosis and **hepatocellular carcinoma** (HCC). 1 For patients with early-stage HCC, there are 3 curative options—ablation, hepatic resection, and **liver transplant** (LT). 2-4 Since the inception of model for end-stage liver disease (MELD)-based ...

[Multidisciplinary approach for post-liver transplant ...](#)

<https://pubmed.ncbi.nlm.nih.gov/30568386>

A large number of liver transplants have been performed for **hepatocellular carcinoma** (HCC), and recurrence is increasingly encountered. The recurrence of HCC after **liver transplantation** is notoriously difficult to manage. We hereby propose multi-disciplinary management with a systematic approach. Th ...

Cited by: 24

Author: Kin Pan Au, Kenneth Siu Ho Chok

Publish Year: 2018

[Sirolimus-based immunosuppression in liver transplantation ...](#)

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.22441>

Sep 30, 2011 · The meta-analysis showed that in comparison with an SRL-free regimen, an SRL-based regimen improved 1-year **patient survival** (OR = 4.53, 95% CI = 2.31-8.89, $P < 0.001$). There was no significant heterogeneity between the studies ($\chi^2 = 0.05$, $P = 0.97$). Two studies reported 3-year **patient survival** (2718 participants).

Cited by: 174

Author: Wenhua Liang, Dongping Wang, Xiaoting ...

Publish Year: 2012